<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39459911</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>07</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>Herpesvirus Antibody Response and Occurrence of Symptoms in Acute and Post-Acute COVID-19 Disease.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1577</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v16101577</ELocationID><Abstract><AbstractText>Knowledge about the underlying causes of the individual occurrence of symptoms during acute COVID-19 disease and during the post-acute sequelae of COVID-19 is limited. In a German COVID-19 follow-up study, we assessed whether elevated antibody responses to herpesviruses were associated with symptom occurrence in acute COVID-19 disease (n = 96 participants) and during 20 months of follow-up (n = 62 participants). Serum samples were analyzed for their antibodies to herpes simplex virus (HSV)-1 and -2, Epstein-Barr virus (EBV), and Cytomegalovirus (CMV) using fluorescent bead-based multiplex serology. The association of herpesvirus antibodies with symptom occurrence (fatigue, fever, dyspnea, decrease in taste, concentration problems) was assessed using multivariate logistic regression models. High EBV antibody levels were significantly associated with a more than fourfold increased odds of experiencing fatigue during acute COVID-19 disease and during follow-up. High CMV antibody levels were significantly associated with a more than threefold increased odds of experiencing concentration problems and a decrease in taste during the follow-up. The HSV-1 and -2 antibody levels were not elevated in the individuals that experienced symptoms. In conclusion, our findings indicate that herpesvirus infections, specifically EBV and CMV infections, might play a role in symptom development during acute and post-acute COVID-19 disease. It remains to be elucidated whether the elevated EBV and CMV antibodies determined in our study are indicators of herpesvirus reactivation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Butt</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Infections and Cancer Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simon</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Infections and Cancer Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waterboer</LastName><ForeName>Tim</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Infections and Cancer Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Merle</LastName><ForeName>Uta</ForeName><Initials>U</Initials><Identifier Source="ORCID">0000-0003-1386-3350</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine IV, University Hospital Heidelberg, 69120 Heidelberg, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Project "High-Throughput Serolomics Open Lab"</GrantID><Agency>Dieter Morszeck Foundation</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003587" MajorTopicYN="N">Cytomegalovirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006566" MajorTopicYN="N">Herpesviridae Infections</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004854" MajorTopicYN="N">Herpesvirus 4, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000917" MajorTopicYN="N">Antibody Formation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018259" MajorTopicYN="N">Herpesvirus 1, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006564" MajorTopicYN="N">Herpesviridae</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003586" MajorTopicYN="N">Cytomegalovirus Infections</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005221" MajorTopicYN="N">Fatigue</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">PASC</Keyword><Keyword MajorTopicYN="N">fatigue</Keyword><Keyword MajorTopicYN="N">herpesvirus</Keyword><Keyword MajorTopicYN="N">serology</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>1</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39459911</ArticleId><ArticleId IdType="pmc">PMC11512323</ArticleId><ArticleId IdType="doi">10.3390/v16101577</ArticleId><ArticleId IdType="pii">v16101577</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>WHO Coronavirus (COVID-19) Dashboard.  [(accessed on 1 June 2024)].  Available online:  https://covid19.who.int/</Citation></Reference><Reference><Citation>World Health Organization . A Clinical Case Definition of Post COVID-19 Condition by a Delphi Consensus, 6 October 2021. World Health Organization; Geneva, Switzerland: 2021.</Citation></Reference><Reference><Citation>Jacob L., Koyanagi A., Smith L., Tanislav C., Konrad M., van der Beck S., Kostev K. Prevalence of, and factors associated with, long-term COVID-19 sick leave in working-age patients followed in general practices in Germany. Int. J. Infect. Dis. 2021;109:203â€“208. doi: 10.1016/j.ijid.2021.06.063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2021.06.063</ArticleId><ArticleId IdType="pmc">PMC8922990</ArticleId><ArticleId IdType="pubmed">34224870</ArticleId></ArticleIdList></Reference><Reference><Citation>Altmann D.M., Whettlock E.M., Liu S., Arachchillage D.J., Boyton R.J. The immunology of long COVID. Nat. Rev. Immunol. 2023;23:618â€“634. doi: 10.1038/s41577-023-00904-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-023-00904-7</ArticleId><ArticleId IdType="pubmed">37433988</ArticleId></ArticleIdList></Reference><Reference><Citation>Franceschini E., Cozzi-Lepri A., Santoro A., Bacca E., Lancellotti G., Menozzi M., Gennari W., Meschiari M., Bedini A., Orlando G., et al. Herpes Simplex Virus Re-Activation in Patients with SARS-CoV-2 Pneumonia: A Prospective, Observational Study. Microorganisms. 2021;9:1896. doi: 10.3390/microorganisms9091896.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms9091896</ArticleId><ArticleId IdType="pmc">PMC8465957</ArticleId><ArticleId IdType="pubmed">34576791</ArticleId></ArticleIdList></Reference><Reference><Citation>SeeÃŸle J., Hippchen T., Schnitzler P., Gsenger J., Giese T., Merle U. High rate of HSV-1 reactivation in invasively ventilated COVID-19 patients: Immunological findings. PLoS ONE. 2021;16:e0254129. doi: 10.1371/journal.pone.0254129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0254129</ArticleId><ArticleId IdType="pmc">PMC8248692</ArticleId><ArticleId IdType="pubmed">34197543</ArticleId></ArticleIdList></Reference><Reference><Citation>Simonnet A., Engelmann I., Moreau A.-S., Garcia B., Six S., El Kalioubie A., Robriquet L., Hober D., Jourdain M. High incidence of Epsteinâ€“Barr virus, cytomegalovirus, and human-herpes virus-6 reactivations in critically ill patients with COVID-19. Infect. Dis. Now. 2021;51:296â€“299. doi: 10.1016/j.idnow.2021.01.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.idnow.2021.01.005</ArticleId><ArticleId IdType="pmc">PMC7816954</ArticleId><ArticleId IdType="pubmed">33495765</ArticleId></ArticleIdList></Reference><Reference><Citation>Carneiro V.C.d.S., Alves-Leon S.V., Sarmento D.J.d.S., Coelho W.L.d.C.N.P., Moreira O.d.C., Salvio A.L., Ramos C.H.F., Filho C.H.F.R., Marques C.A.B., GonÃ§alves J.P.d.C., et al. Herpesvirus and neurological manifestations in patients with severe coronavirus disease. Virol. J. 2022;19:101. doi: 10.1186/s12985-022-01828-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-022-01828-9</ArticleId><ArticleId IdType="pmc">PMC9174631</ArticleId><ArticleId IdType="pubmed">35676707</ArticleId></ArticleIdList></Reference><Reference><Citation>Weber S., Kehl V., Erber J., Wagner K.I., Jetzlsperger A.-M., Burrell T., Schober K., Schommers P., Augustin M., Crowell C.S., et al. CMV seropositivity is a potential novel risk factor for severe COVID-19 in non-geriatric patients. PLoS ONE. 2022;17:e0268530. doi: 10.1371/journal.pone.0268530.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0268530</ArticleId><ArticleId IdType="pmc">PMC9132318</ArticleId><ArticleId IdType="pubmed">35613127</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernal K.D.E., Whitehurst C.B. Incidence of Epstein-Barr virus reactivation is elevated in COVID-19 patients. Virus Res. 2023;334:199157. doi: 10.1016/j.virusres.2023.199157.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2023.199157</ArticleId><ArticleId IdType="pmc">PMC10292739</ArticleId><ArticleId IdType="pubmed">37364815</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks B., Tancredi C., Song Y., Mogus A.T., Huang M.-L.W., Zhu H., Phan T.L., Zhu H., Kadl A., Woodfolk J., et al. Epsteinâ€“Barr Virus and Human Herpesvirus-6 Reactivation in Acute COVID-19 Patients. Viruses. 2022;14:1872. doi: 10.3390/v14091872.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14091872</ArticleId><ArticleId IdType="pmc">PMC9504756</ArticleId><ArticleId IdType="pubmed">36146679</ArticleId></ArticleIdList></Reference><Reference><Citation>Manoharan S., Ying L.Y. Epstein Barr Virus Reactivation during COVID-19 Hospitalization Significantly Increased Mortality/Death in SARS-CoV-2(+)/EBV(+) than SARS-CoV-2(+)/EBV(âˆ’) Patients: A Comparative Meta-Analysis. Int. J. Clin. Pr. 2023;2023:1068000. doi: 10.1155/2023/1068000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2023/1068000</ArticleId><ArticleId IdType="pmc">PMC9904914</ArticleId><ArticleId IdType="pubmed">36793928</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z., Hollmann C., Kalanidhi S., Grothey A., Keating S., Mena-Palomo I., Lamer S., Schlosser A., Kaiping A., Scheller C., et al. Increased circulating fibronectin, depletion of natural IgM and heightened EBV, HSV-1 reactivation in ME/CFS and long COVID. medRxiv. 2023:Preprint. doi: 10.1101/2023.06.23.23291827.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.06.23.23291827</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein J., Wood J., Jaycox J., Lu P., Dhodapkar R.M., Gehlhausen J.R., Tabachnikova A., Tabacof L., Malik A.A., Kamath K., et al. Distinguishing features of Long COVID identified through immune profiling. medRxiv. 2022 doi: 10.1038/s41586-023-06651-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-06651-y</ArticleId><ArticleId IdType="pmc">PMC10620090</ArticleId><ArticleId IdType="pubmed">37748514</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso M.J., Deveau T.-M., Munter S.E., Ryder D., Buck A., Beck-Engeser G., Chan F., Lu S., Goldberg S.A., Hoh R., et al. Chronic viral coinfections differentially affect the likelihood of developing long COVID. J. Clin. Investig. 2023;133:e163669. doi: 10.1172/jci163669.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci163669</ArticleId><ArticleId IdType="pmc">PMC9888380</ArticleId><ArticleId IdType="pubmed">36454631</ArticleId></ArticleIdList></Reference><Reference><Citation>Zubchenko S., Kril I., Nadizhko O., Matsyura O., Chopyak V. Herpesvirus infections and post-COVID-19 manifestations: A pilot observational study. Rheumatol. Int. 2022;42:1523â€“1530. doi: 10.1007/s00296-022-05146-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-022-05146-9</ArticleId><ArticleId IdType="pmc">PMC9159383</ArticleId><ArticleId IdType="pubmed">35650445</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y., Yuan D., Chen D.G., Ng R.H., Wang K., Choi J., Li S., Hong S., Zhang R., Xie J., et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;185:881â€“895.e20. doi: 10.1016/j.cell.2022.01.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.014</ArticleId><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold J.E., Okyay R.A., Licht W.E., Hurley D.J. Investigation of Long COVID Prevalence and Its Relationship to Epstein-Barr Virus Reactivation. Pathogens. 2021;10:763. doi: 10.3390/pathogens10060763.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens10060763</ArticleId><ArticleId IdType="pmc">PMC8233978</ArticleId><ArticleId IdType="pubmed">34204243</ArticleId></ArticleIdList></Reference><Reference><Citation>Apostolou E., Rizwan M., Moustardas P., SjÃ¶gren P., Bertilson B.C., BragÃ©e B., Polo O., RosÃ©n A. Saliva antibody-fingerprint of reactivated latent viruses after mild/asymptomatic COVID-19 is unique in patients with myalgic-encephalomyelitis/chronic fatigue syndrome. Front. Immunol. 2022;13:949787. doi: 10.3389/fimmu.2022.949787.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.949787</ArticleId><ArticleId IdType="pmc">PMC9630598</ArticleId><ArticleId IdType="pubmed">36341457</ArticleId></ArticleIdList></Reference><Reference><Citation>Klenerman P., Oxenius A. T cell responses to cytomegalovirus. Nat. Rev. Immunol. 2016;16:367â€“377. doi: 10.1038/nri.2016.38.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri.2016.38</ArticleId><ArticleId IdType="pubmed">27108521</ArticleId></ArticleIdList></Reference><Reference><Citation>Waterboer T., Sehr P., Michael K.M., Franceschi S., Nieland J.D., O Joos T., Templin M.F., Pawlita M. Multiplex human papillomavirus serology based on in situâ€“purified glutathione s-transferase fusion proteins. Clin. Chem. 2005;51:1845â€“1853. doi: 10.1373/clinchem.2005.052381.</Citation><ArticleIdList><ArticleId IdType="doi">10.1373/clinchem.2005.052381</ArticleId><ArticleId IdType="pubmed">16099939</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner N., Mentzer A.J., Butt J., Michel A., Prager K., Brozy J., WeiÃŸbrich B., Aiello A.E., Meier H.C.S., Breuer J., et al. Validation of Multiplex Serology detecting human herpesviruses 1-5. PLoS ONE. 2018;13:e0209379. doi: 10.1371/journal.pone.0209379.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0209379</ArticleId><ArticleId IdType="pmc">PMC6307738</ArticleId><ArticleId IdType="pubmed">30589867</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon J., Brenner N., Reich S., Langseth H., Hansen B.T., Ursin G., Ferreiro-Iglesias A., Brennan P., Kreimer A.R., Johansson M., et al. Nasopharyngeal carcinoma patients from Norway show elevated Epstein-Barr virus IgA and IgG antibodies prior to diagnosis. Cancer Epidemiol. 2022;77:102117. doi: 10.1016/j.canep.2022.102117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.canep.2022.102117</ArticleId><ArticleId IdType="pmc">PMC11287450</ArticleId><ArticleId IdType="pubmed">35121404</ArticleId></ArticleIdList></Reference><Reference><Citation>Feederle R., Kost M., Baumann M., Janz A., Drouet E., Hammerschmidt W., Delecluse H. The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators. EMBO J. 2000;19:3080â€“3089. doi: 10.1093/emboj/19.12.3080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/emboj/19.12.3080</ArticleId><ArticleId IdType="pmc">PMC203345</ArticleId><ArticleId IdType="pubmed">10856251</ArticleId></ArticleIdList></Reference><Reference><Citation>Littler E., Zeuthen J., McBride A., SÃ¸rensen E.T., Powell K., Walsh-Arrand J., Arrand J. Identification of an Epstein-Barr virus-coded thymidine kinase. EMBO J. 1986;5:1959â€“1966. doi: 10.1002/j.1460-2075.1986.tb04450.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/j.1460-2075.1986.tb04450.x</ArticleId><ArticleId IdType="pmc">PMC1167064</ArticleId><ArticleId IdType="pubmed">3019675</ArticleId></ArticleIdList></Reference><Reference><Citation>Song L., Song M., Camargo M.C., Van Duine J., Williams S., Chung Y., Kim K.-M., Lissowska J., Sivins A., Gao W., et al. Identification of anti-Epstein-Barr virus (EBV) antibody signature in EBV-associated gastric carcinoma. Gastric Cancer. 2021;24:858â€“867. doi: 10.1007/s10120-021-01170-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10120-021-01170-z</ArticleId><ArticleId IdType="pmc">PMC8206016</ArticleId><ArticleId IdType="pubmed">33661412</ArticleId></ArticleIdList></Reference><Reference><Citation>SeeÃŸle J., Waterboer T., Hippchen T., Simon J., Kirchner M., Lim A., MÃ¼ller B., Merle U. Persistent Symptoms in Adult Patients 1 Year After Coronavirus Disease 2019 (COVID-19): A Prospective Cohort Study. Clin. Infect. Dis. 2021;74:1191â€“1198. doi: 10.1093/cid/ciab611.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab611</ArticleId><ArticleId IdType="pmc">PMC8394862</ArticleId><ArticleId IdType="pubmed">34223884</ArticleId></ArticleIdList></Reference><Reference><Citation>Munblit D., Nicholson T., Akrami A., Apfelbacher C., Chen J., De Groote W., Diaz J.V., Gorst S.L., Harman N., Kokorina A., et al. A core outcome set for post-COVID-19 condition in adults for use in clinical practice and research: An international Delphi consensus study. Lancet Respir. Med. 2022;10:715â€“724. doi: 10.1016/S2213-2600(22)00169-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(22)00169-2</ArticleId><ArticleId IdType="pmc">PMC9197249</ArticleId><ArticleId IdType="pubmed">35714658</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>